Fortunately, these giant rings are about to become a lot easier to access. Helma Wennemers and her team at ETH Zurich have ...

Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in 2026 and beyond PISCATAWAY, N.J., Jan. 29, 2026 /PRNewswire/ -- GenScript Biotech ...

The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A. Credit...Hannah Agosta Supported by By Jasmine Sun Jayden Clark first heard about ...

The two companies enter into a multi-year strategic agreement to accelerate drug development timelines, strengthen U.S. manufacturing capabilities and help bring lifesaving medicines to patients ...

A suite of products promise smoother skin, bigger muscles and longer life. But what are peptides? And do they work? By David Dodge It seems as if everywhere you turn, celebrities and influencers are ...

The average one-year price target for Genscript Biotech (OTCPK:GNNSF) has been revised to $3.32 / share. This is an increase of 16.00% from the prior estimate of $2.86 dated April 1, 2025. The price ...

Officials at India-based Syngene International, a CRDMO, report that the company executed site upgrades to accelerate drug discovery and development. The investments included a dedicated peptide ...

A peptide sequence that performs well at micromole scale may behave unpredictably at gram or kilogram scale. Coupling efficiency, acceptable with high reagent excess, can drop when equivalents are ...

Genscript Biotech Corporation ((HK:1548)) has held its Q2 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Vapourtec's Peptide-Builder, a fully automated, high-throughput benchtop peptide synthesizer, has been designed to redefine solid-phase peptide synthesis (SPPS). Compact, efficient and intuitive, it ...